AML-associated Flt3 kinase domain mutations show signal transduction differences compared with Flt3 ITD mutations - PubMed (original) (raw)
. 2005 Jul 1;106(1):265-73.
doi: 10.1182/blood-2004-07-2942. Epub 2005 Mar 15.
Affiliations
- PMID: 15769897
- DOI: 10.1182/blood-2004-07-2942
Free article
AML-associated Flt3 kinase domain mutations show signal transduction differences compared with Flt3 ITD mutations
Chunaram Choudhary et al. Blood. 2005.
Free article
Abstract
Activating mutations of Flt3 are found in approximately one third of patients with acute myeloid leukemia (AML) and are an attractive drug target. Two classes of Flt3 mutations occur: internal tandem duplications (ITDs) in the juxtamembrane and point mutations in the tyrosine kinase domain (TKD). We and others have shown that Flt3-ITD induced aberrant signaling including strong activation of signal transducer and activator of transcription 5 (STAT5) and repression of CCAAT/estradiol-binding protein alpha (c/EBPalpha) and Pu.1. Here, we compared the signaling properties of Flt3-ITD versus Flt3-TKD in myeloid progenitor cells. We demonstrate that Flt3-TKD mutations induced autonomous growth of 32D cells in suspension cultures. However, in contrast to Flt3-ITD and similar to wild-type Flt3 (Flt3-WT), Flt3-TKD cannot support colony formation in semisolid media. Also, in contrast to Flt3-ITD, neither Flt3-WT nor Flt3-TKD induced activation or induction of STAT5 target genes. Flt3-TKD also failed to repress c/EBPalpha and Pu.1. No significant differences were observed in receptor autophosphorylation and the phosphorylation of Erk-1 and -2, Akt, and Shc. Importantly, TKD but not ITD mutations were a log power more sensitive toward the tyrosine kinase inhibitor protein kinase C 412 (PKC412) than Flt3-WT. In conclusion, Flt3-ITD and Flt3-TKD mutations display differences in their signaling properties that could have important implications for their transforming capacity and for the design of mutation-specific therapeutic approaches.
Similar articles
- Mutations in the tyrosine kinase domain of FLT3 define a new molecular mechanism of acquired drug resistance to PTK inhibitors in FLT3-ITD-transformed hematopoietic cells.
Bagrintseva K, Schwab R, Kohl TM, Schnittger S, Eichenlaub S, Ellwart JW, Hiddemann W, Spiekermann K. Bagrintseva K, et al. Blood. 2004 Mar 15;103(6):2266-75. doi: 10.1182/blood-2003-05-1653. Epub 2003 Nov 6. Blood. 2004. PMID: 14604974 - FLT3-ITD and tyrosine kinase domain mutants induce 2 distinct phenotypes in a murine bone marrow transplantation model.
Grundler R, Miething C, Thiede C, Peschel C, Duyster J. Grundler R, et al. Blood. 2005 Jun 15;105(12):4792-9. doi: 10.1182/blood-2004-11-4430. Epub 2005 Feb 17. Blood. 2005. PMID: 15718420 - Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways.
Mizuki M, Fenski R, Halfter H, Matsumura I, Schmidt R, Müller C, Grüning W, Kratz-Albers K, Serve S, Steur C, Büchner T, Kienast J, Kanakura Y, Berdel WE, Serve H. Mizuki M, et al. Blood. 2000 Dec 1;96(12):3907-14. Blood. 2000. PMID: 11090077 - [FLT3 Mutations in Acute Myeloid Leukemia].
Shoji T, Kida Y, Yamashita K, Ichiyama S. Shoji T, et al. Rinsho Byori. 2017 Jan;65(1):44-51. Rinsho Byori. 2017. PMID: 30695511 Review. Japanese. - Flt3 receptor tyrosine kinase as a drug target in leukemia.
Schmidt-Arras D, Schwäble J, Böhmer FD, Serve H. Schmidt-Arras D, et al. Curr Pharm Des. 2004;10(16):1867-83. doi: 10.2174/1381612043384394. Curr Pharm Des. 2004. PMID: 15180525 Review.
Cited by
- Activating mutations remodel the chromatin accessibility landscape to drive distinct regulatory networks in _KMT2A_-rearranged acute leukemia.
Zhang Q, Falqués-Costa T, Pilheden M, Sturesson H, Ovlund T, Rissler V, Castor A, Marquart HVH, Lausen B, Fioretos T, Hyrenius-Wittsten A, Hagström-Andersson AK. Zhang Q, et al. Hemasphere. 2024 Sep 26;8(9):e70006. doi: 10.1002/hem3.70006. eCollection 2024 Sep. Hemasphere. 2024. PMID: 39329074 Free PMC article. - Glycosylation: mechanisms, biological functions and clinical implications.
He M, Zhou X, Wang X. He M, et al. Signal Transduct Target Ther. 2024 Aug 5;9(1):194. doi: 10.1038/s41392-024-01886-1. Signal Transduct Target Ther. 2024. PMID: 39098853 Free PMC article. Review. - Ningetinib, a novel FLT3 inhibitor, overcomes secondary drug resistance in acute myeloid leukemia.
Hu C, Zhang Y, Yang J, Xu Y, Deng T, Li Y, Xu S, Wang S, Wang P. Hu C, et al. Cell Commun Signal. 2024 Jul 8;22(1):355. doi: 10.1186/s12964-024-01729-0. Cell Commun Signal. 2024. PMID: 38978049 Free PMC article. - Importance of PTM of FLT3 in acute myeloid leukemia.
Liu J, Gu J. Liu J, et al. Acta Biochim Biophys Sin (Shanghai). 2024 Jun 24;56(8):1199-1207. doi: 10.3724/abbs.2024112. Acta Biochim Biophys Sin (Shanghai). 2024. PMID: 38915288 Free PMC article. Review. - Emerging DNA Methylome Targets in FLT3-ITD-Positive Acute Myeloid Leukemia: Combination Therapy with Clinically Approved FLT3 Inhibitors.
Tecik M, Adan A. Tecik M, et al. Curr Treat Options Oncol. 2024 Jun;25(6):719-751. doi: 10.1007/s11864-024-01202-7. Epub 2024 May 2. Curr Treat Options Oncol. 2024. PMID: 38696033 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous